Randomised Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment, compared to continued standard first-line systemic treatment in patients with unresectable oligometastatic CRC.

Primary Sponsor

Australasian Gastro-Intestinal Trials Group (AGITG)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

50

Expected Date of Accrual

31 December 2026

Trial Chairperson

Dr Julie Chu, Peter MacCallum Cancer Centre, VIC, Australia

Trial Contact

qa@trog.com.au

Related Post

HeSANDA database for clinical trial data
21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

SMART trial grant
16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed